Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PMDA Chief Resigns In Wake Of Hepatitis C Controversy

This article was originally published in PharmAsia News

Executive Summary

Former Japan Pharmaceutical and Food Bureau Chief, Akira Miyajima, resigned on Jan. 17 as CEO of the Pharmaceutics and Medical Devices Agency. His resignation is believed to be an effort to take responsibility for brushing aside a list of hepatitis C cases caused by contaminated blood products, and failing to notify patients about the information (PharmAsia News, Jan. 17, 2008). In August 2002, the Ministry of Health, Labor and Welfare received a list from pharmaceutical companies of the cases of 418 hepatitis C patients; the information included duration of drug administration and each patient's symptoms. However, the list was not delivered to the patients themselves. It is believed that the failure to transmit this information led to a worsening in the cases. (click here for more - may require subscription
Advertisement

Related Content

Japan Hepatitis C Settlement Set To Cover Only 10 Percent
Advertisement
UsernamePublicRestriction

Register

SC066671

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel